Ticker League

Net Income for Vertex Pharmaceuticals (VRTX)

Latest filings through · Reported

Metric

TTM

$4.34B

YoY change

-838.1%

5Y CAGR

+7.8%

Peak year (2025)

$3.95B

Net Income history chart for Vertex Pharmaceuticals (VRTX) from 1990 to 2025

Latest: $3.95B

Net Income growth chart for Vertex Pharmaceuticals (VRTX) from 1990 to 2025

Latest: -838.1%

Net Income history table for Vertex Pharmaceuticals (VRTX) from 1990 to 2025

  • 2025$3.95B-838.1%
  • 2024−$535.60M-114.8%
  • 2023$3.62B+9.0%
  • 2022$3.32B+41.8%
  • 2021$2.34B-13.6%
  • 2020$2.71B+130.4%
  • 2019$1.18B-43.9%
  • 2018$2.10B+695.8%
  • 2017$263.48M-335.1%
  • 2016−$112.05M-79.9%
  • 2015−$558.12M-24.4%
  • 2014−$738.55M+66.0%
  • 2013−$445.03M+315.8%
  • 2012−$107.03M-461.9%
  • 2011$29.57M-103.9%
  • 2010−$754.63M+17.6%
  • 2009−$641.58M+39.5%
  • 2008−$459.85M+17.5%
  • 2007−$391.28M+89.1%
  • 2006−$206.89M+1.7%
  • 2005−$203.42M+22.4%
  • 2004−$166.25M-15.5%
  • 2003−$196.77M+81.2%
  • 2002−$108.62M+64.0%
  • 2001−$66.23M+67.0%
  • 2000−$39.66M-3.3%
  • 1999−$41.00M+23.9%
  • 1998−$33.10M+67.2%
  • 1997−$19.80M-50.5%
  • 1996−$40.00M+86.0%
  • 1995−$21.50M+22.2%
  • 1994−$17.60M-980.0%
  • 1993$2.00M-123.5%
  • 1992−$8.50M+66.7%
  • 1991−$5.10M+18.6%
  • 1990−$4.30M—

Net Income values are taken from Vertex Pharmaceuticals's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.

About Net Income at Vertex Pharmaceuticals (VRTX)

According to Vertex Pharmaceuticals's latest reported financial statements, the company's current net income (TTM) is $4.34B. Net income is the bottom-line profit after all expenses — cost of goods sold, operating expenses, interest, and taxes — are subtracted from revenue. It is the figure used to compute earnings per share (EPS) and is the residual available to shareholders.

Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .

2025's annual net income for Vertex Pharmaceuticals (VRTX) came in at $3.95B – plunged 838.1% year-over-year.

Vertex Pharmaceuticals net income compound annual growth for the 2020–2025 (5 years) window is +7.8%, with mixed annual results across the window.

2025 marks the peak net income at $3.95B, with the historical low of −$754.63M recorded in 2010.

Vertex Pharmaceuticals Net Income by Year

Vertex Pharmaceuticals Net Income 2025: $3.95B

Vertex Pharmaceuticals posted net income of $3.95B in 2025, plunged 838.1% below 2024. This figure represents the highest annual value in the available history.

Vertex Pharmaceuticals Net Income 2024: −$535.60M

In 2024, Vertex Pharmaceuticals reported net income of −$535.60M, plunged 114.8% below 2023.

Vertex Pharmaceuticals Net Income 2023: $3.62B

Vertex Pharmaceuticals net income in 2023 was $3.62B, grew 9.0% from 2022.

Vertex Pharmaceuticals Net Income 2022: $3.32B

2022's net income for Vertex Pharmaceuticals came in at $3.32B, surged 41.8% from 2021.

Vertex Pharmaceuticals Net Income 2021: $2.34B

Vertex Pharmaceuticals net income in 2021 was $2.34B.

See more financial history for Vertex Pharmaceuticals (VRTX).

Sector peers by Net Income

Healthcare peers of Vertex Pharmaceuticals (VRTX), ranked by their latest net income

Frequently asked questions

Vertex Pharmaceuticals (VRTX) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation